Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Researchers at Acadia University find that wine drinkers are more accepting of pasta sauce formulated with the addition of grape pomace than those who do not drink wine.

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

To support patients, BridgeBio will provide Attruby free for life to U.S. clinical trial participants. The company has also ...

The FDA announced a new pilot program for communication of medical device recalls, but industry may be wary of a program that ...

We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.